GBI International
NEW

PITDC Leads Delegation to Seek Opportunities in Pharmaceutical Manufacturing Hub in Germany
GBI International
NEW

Taiwan Pharmaceutical Alliance Engages at 2025 CPHI to Boost International Cooperation and Exports

GBI International
NEW

Spirit Scientific Wins Double Bronze for Regenerative Medicine Innovation at TIE 2025

GBI International
GBIHighlights AIinHealthcare MayoClinic

AESOP Technology Joins Mayo Clinic Platform

2025-10-28/GlobalBio & Investment
BigCongratulationstoAESOPTechnology!AESOPTechnologyJoinsMayoClinicPlatform!AESOPTechnology’sAI-drivendiagnosticsupportsolution,DxPrime,isnowofficiallyaqualifiedsolutionontheMayoClinicPlatform&md...
GBI International
GBIHighlights BPIPO BioJapan BioJapan2025

Taiwan Biotech Makes a Strong Statement at BioJapan 2025!

2025-10-14/GlobalBio & Investment
ThemomentumatBioJapan2025surpassedallpreviousyears!FromOctober8–10,theannualbiotecheventheldatPacificoYokohamadrewover9,000participants,markinga137%increasefromlastyear. KeyHighlights:StrongTaiw...
GBI International
GBIHighlights CellTherapy Exosome

Ever Supreme Bio Acquires Shine Out Biotech for NT$1.7B

2025-10-07/GlobalBio & Investment
Inaboldstrategicmove,EverSupremeBioTechnologyCo.,Ltd.announcedaNT$1.7billionall-shareacquisitionofShineOutBiotechnologyCo.,Ltd.,aimingtoaccelerateitspositioninexosometherapeuticsandcell-baseddruginnov...
GBI International
GBIHighlights PostpartumDepression

TWi Biotechnology’s Postpartum Depression Drug Completes U.S. Phase II Enrollment

2025-09-24/GlobalBio & Investment
TWiBiotechnology’sPostpartumDepressionDrugCompletesU.S.PhaseIIEnrollment TWiBiotechnologyInc.(6610)announcedthatitsoraldrugcandidateNORA520,developedforpostpartumdepression(PPD),hascompletedpati...
GBI International
GBIHighlights Immunotherapy Antibodies Oncology

AP Biosciences advances next-generation bispecific antibody therapies for solid tumor immunotherapy

2025-09-22/GlobalBio & Investment
APBiosciences,Inc.isadvancingnext-generationCD137bispecificantibodytherapiesforsolidtumorimmunotherapy. AttheTaiwanImmuno-OncologyDrugDevelopmentForum,founderDr.JengHersharedhowAPBiosciencesisdifferen...
GBI International
GBIHighlights Apollomics Apollomics Nasdaq

Apollomics Announces Receipt of Nasdaq Delisting Notification, and Will Appeal to Retain Nasdaq List

2025-09-22/新聞中心
ApollomicsInc.(Nasdaq:APLM)(“Apollomics”orthe“Company”),aCaliforniabasedlate-stageclinicalbiopharmaceuticalcompanydevelopingmultipleoncologydrugcandidatestoaddressdifficult-to-...
GBI International
GBIHighlights biobook

In memory of Dr. Chao-pin Hsu—Discover How One Doctor is Transforming Rural Healthcare

2025-09-19/GlobalBio & Investment
Dr.Chao-pinHsu,DjaikungLuveljeng,knownasthe"SuperDoctor,"haspassedawayon18thSep,2025.Hededicatedhislifetoservingruralcommunities,yetleavesbehindtheunfinisheddreamofcompletingtheSouth-LinkMed...
GBI International
GBIHighlights Oncology mRNA Immunotherapy

Elixiron Targets T-Cell Exhaustion with Next-Gen Cancer Immunotherapies

2025-09-18/GlobalBio & Investment
On16thSeptember,Dr.Hung-KaiChen,Founder&CEOofElixironImmunotherapeutics,sharedthecompany’sinnovativepipelineaddressingoneofthetoughestchallengesinoncology—TcellexhaustionattheTaiwanImm...
GBI International
GBIHighlights NVIDIATAIPEI-1 AIdrugs ADC CAR-T

Topmunnity Secures 2nd Place in NVIDIA TAIPEI-1 Review

2025-09-18/GlobalBio & Investment
TopmunnityEarns2ndPlaceinNVIDIATAIPEI-1Review,StandingOutastheOnlyTeaminAIDrugDevelopment.On15thSeptember,CEOofTopmunnity AmyHuang(Chao-YuanHuang)announcedthatTopmunnity'sproposal,"One-StopGe...
GBI International
GBIHighlights ICI Immunotherapy Oncology

GNT Biotech Advances GNTbm-38 with IND Filings in US & China by 2026

2025-09-18/GlobalBio & Investment
GNTBiotech&MedicalsCorporation(GNTbm)isadvancingGNTbm-38,anext-generationoralimmuno-regulatorydrug,withINDfilingsplannedintheUS&Chinabyearly2026.InvestmentHighlightsGlobalIPStrength:38inventio...
GBI International
GBIHighlights BNCT CancerTherapy

BNCT in Taiwan! Heron Neutron surges on IPO debut

2025-09-17/GlobalBio & Investment
HeronNeutronMedicalCorp(7799.TW)madeastellardebutthisweek,listingatNT$600andsoaringnearly29%,overtakingBoraPharmaceuticals(6472.TW)asTaiwan'snewbiotechIPOleader.Foundedin2017,HeronNeutronpioneersA...
GBI International
GBIHighlights M&A Pharma

Synmosa Biopharma Moves to Acquire up to 30% of Genovate Bio at a 30% Premium

2025-09-16/新聞中心
SynmosaBiopharma (4114.TWO)announcedthatitsBoardhasapprovedaplantoacquire15%–30%ofGenovateBio (4130.TWO)sharesthroughapublictenderofferatNT$24pershare—a30%premiumoverGenovate'slatestcl...

TOP
  • Global Bio and Investment Monthly
  • 讀者服務電話：+886 2 2726 1065時間：週一 ~ 週五 09:00 ~ 18:00
  • 服務信箱：[email protected]
  • 地址：110臺北市信義區信義路六段29號2樓之一, Taiwan

我們的服務